The global Biopharmaceutical CMO And CRO Market size was valued at USD 36.8 billion in 2022, and the market is projected to reach USD 57.2 billion by the end of 2023, with growth at a CAGR of 6.5% during the forecast report 2023-2030.
The biopharmaceutical CMO (Contract Manufacturing Organization) and CRO (Contract Research Organization) market refers to the outsourcing of manufacturing and research activities by the pharmaceutical and biotech sectors to external service providers.
The market for CMO and CRO services has been progressively growing as outsourcing has become more popular among pharmaceutical and biotech companies as a way to save costs and increase efficiency. While CMOs produce biologic drugs, vaccines, and other complex medicines, CROs provide research services including preclinical and clinical trial services, drug discovery, and development help.
The need for biologics and individualized medicine, the necessity for effective drug development, and other factors are expected to contribute to the rapid growth of the global biopharmaceutical CMO and CRO market in the coming years.
Lonza, Catalent, Thermo Fisher Scientific, Parexel, IQVIA, and Syneos Health are important market participants in the biopharmaceutical CMO and CRO sectors. Manufacturing, formulation development, analytical testing, clinical trial management, and regulatory assistance are just a few of the services that these businesses provide.
It is anticipated that the biopharmaceutical CMO and CRO market would expand during the next years as more pharmaceutical and biotech businesses outsource their drug development activities to increase productivity and save costs.
Increasing demand for biologics: Biologics, which are drugs produced from living cells, are increasingly popular due to their efficacy and potential to treat previously untreatable diseases. This has led to a surge in demand for CMOs that specialize in biological manufacturing.
The growing importance of personalized medicine: Personalized medicine, which involves tailoring treatments to an individual's unique genetic makeup, is becoming increasingly important. CMOs and CROs are playing a vital role in developing personalized therapies, including manufacturing customized cell and gene therapies.
The emergence of new technologies: Advances in technology, such as gene editing and synthetic biology, are changing the way drugs are developed and manufactured. CMOs and CROs need to be agile and adaptable to keep pace with these developments.
Increasing regulatory complexity: The pharmaceutical regulatory landscape is become more intricate and stricter, especially for biologics. To guide their clients through the drug development process, CMOs, and CROs must have a thorough awareness of regulatory regulations.
Growth of developing markets: The global pharmaceutical business is seeing an increase in the importance of emerging countries like China and India. To take advantage of the growing prospects these sectors present, CMOs and CROs are increasing their market share. COVID-19's effects on the biopharmaceutical sector, especially the CMO and CRO markets, have been significant. Due to the pandemic, there is now a higher demand for outsourcing services as businesses try to create COVID-19 vaccines and treatments faster and shorten drug development delays.
As per the report, the global Biopharmaceutical CMO And CRO Market is segmented into Type, Application, and Regions. The report covers detailed information on market size, Share, Growth, Value, Volume Analysis, Demand analysis, new market entry, competition insights, market drivers, challenges, opportunities, and Restraints. Further, company profile analysis, company revenue, Strategies, Sales, company acquisition, partnership, mergers, latest trends in the industry, regional and country-level insights, and competitive intelligence data is provided in the research report.
Further, the global market is geographically divided into major regions, and countries including North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Further, major countries focused in the global study report: United States, Canada, United Kingdom, Spain, Germany, Italy, France, Mexico, Russia, Ukraine, China, Japan, South Korea, India, Singapore, Malaysia, Australia, Qatar, Kingdom of Saudi Arabia, South Africa, Brazil, Argentina, and other countries are covered in the research study.
• Mammalian
• Non-mammalian
By Service
• Contract Manufacturing
• Contract Research
• Monoclonal antibodies (MAbs)
• Recombinant Proteins
• Vaccines
• Antisense, RNAi, & Molecular Therapy
• Biosimilars
• Others
Geographical Classification Analysis:
- North America
- Latin America
- Europe
- Middle East and Africa
- Asia Pacific
Regional Insights:
• North American market to remain in control over the global market during 2022-2030. In the North American region, the United States occupied the highest share of the market in this region, and the US country is projected to follow the same trend over the forecast time 2022-2030, followed by Canada.
• Europe holds the second largest share producer in the global Disposable Medical Sensors Market during the forecast period 2022-2030. Asia Pacific region is expected to be registered as the fastest-growing market in the global market by 2030.
• Most developing countries in the Asia Pacific remain the focus of leading Disposable Medical Sensors companies, with a large portion of these companies investing in new entry and business expansion strategies
• The market in the Middle East and Africa is projected to show prominent growth opportunities in the coming years from 2023-2030. Due to the rising focus from the government of the Middle East and African countries on emerging healthcare infrastructure manufacturing and distribution are mostly contributing to the global market in the MEA region.
• The Latin American Disposable Medical Sensors Market registered a substantial share of the global market in 2022, and it is projected to remain its presence in the market.
• Boehringer Ingelheim GmbH
• Lonza Group
• Inno Biologics Sdn Bhd
• Rentschler Biopharma SE
• JRS Pharma
• Biomeva GmbH
• ProBioGen AG
• Fujifilm Holdings Corporation
• Toyobo Co. Ltd.
1. Executive Summary
1.1 Introduction to Biopharmaceutical CMO And CRO Markets
1.2 Biopharmaceutical CMO And CRO Market Size Outlook, 2021- 2030
1.3 Growth Opportunities in Biopharmaceutical CMO And CRO Industry
1.4 Winning Strategies for the post-pandemic future
2. Report Guide
2.1 Market Definition and Scope
2.2 Market Segmentation
2.3 Research Methodology
2.4 Forecast Methodology
2.5 List of Abbreviations
3. Growth Opportunity Analysis
3.1 Key Biopharmaceutical CMO And CRO Market Trends
3.2 Key Biopharmaceutical CMO And CRO Market Growth Drivers
3.3 Key Biopharmaceutical CMO And CRO Market Growth Restraints
4 Biopharmaceutical CMO And CRO Market Outlook – Scenario Analysis
4.1 Low Growth Case Scenario Forecasts
4.2 Reference Growth Case Scenario Forecasts
4.3 High Growth Case Scenario Forecasts
5. Biopharmaceutical CMO And CRO Market Segmentation- Outlook by Source
5.1 Mammalian Market Outlook to 2030
5.2 Non-mammalian Market Outlook to 2030
6. Biopharmaceutical CMO And CRO Market Segmentation- Outlook by Service
6.1 Contract Manufacturing Market Outlook to 2030
6.2 Contract Research Market Outlook to 2030
7. Biopharmaceutical CMO And CRO Market Segmentation- Outlook by Product
7.1 Monoclonal antibodies (MAbs) Market Outlook to 2030
7.2 Recombinant Proteins Market Outlook to 2030
7.3 Vaccines Market Outlook to 2030
7.4 Antisense, RNAi, & Molecular Therapy Market Outlook to 2030
7.5 Biosimilars Market Outlook to 2030
7.6 Others Market Outlook to 2030
8. North America Biopharmaceutical CMO And CRO Market Outlook and Opportunities to 2030
8.1 Market Snapshot, 2023
8.2 North America Biopharmaceutical CMO And CRO Market Growth Opportunities
8.3 North America Biopharmaceutical CMO And CRO Market Outlook by Application
8.4 North America Biopharmaceutical CMO And CRO Market Outlook by Type
8.5 North America Biopharmaceutical CMO And CRO Market Outlook by Country
8.6 United States Biopharmaceutical CMO And CRO Market Outlook
8.7 Canada Biopharmaceutical CMO And CRO Market Outlook
8.8 Mexico Biopharmaceutical CMO And CRO Market Outlook
9. Europe Biopharmaceutical CMO And CRO Market Outlook and Opportunities to 2030
9.1 Market Snapshot, 2023
9.2 Europe Biopharmaceutical CMO And CRO Market Outlook by Application
9.3 Europe Biopharmaceutical CMO And CRO Market Outlook by Type
9.4 Europe Biopharmaceutical CMO And CRO Market Outlook by Country
9.5 Germany Biopharmaceutical CMO And CRO Market Outlook
9.6 France Biopharmaceutical CMO And CRO Market Outlook
9.7 United Kingdom Biopharmaceutical CMO And CRO Market Outlook
9.8 Spain Biopharmaceutical CMO And CRO Market Outlook
9.9 Italy Biopharmaceutical CMO And CRO Market Outlook
9.10 Other Europe Biopharmaceutical CMO And CRO Market Outlook
10. Asia Pacific Biopharmaceutical CMO And CRO Market Outlook and Opportunities to 2030
10.1 Market Snapshot, 2023
10.2 Asia Pacific Biopharmaceutical CMO And CRO Market Outlook by Application
10.3 Asia Pacific Biopharmaceutical CMO And CRO Market Outlook by Type
10.4 Asia Pacific Biopharmaceutical CMO And CRO Market Outlook by Country
10.5 China Biopharmaceutical CMO And CRO Market Outlook
10.6 Japan Biopharmaceutical CMO And CRO Market Outlook
10.7 India Biopharmaceutical CMO And CRO Market Outlook
10.8 Other Asia Pacific Biopharmaceutical CMO And CRO Market Outlook
11. Latin America Biopharmaceutical CMO And CRO Market Outlook and Opportunities to 2030
11.1 Market Snapshot, 2023
11.2 Latin America Biopharmaceutical CMO And CRO Market Outlook by Application
11.3 Latin America Biopharmaceutical CMO And CRO Market Outlook by Type
11.4 Latin America Biopharmaceutical CMO And CRO Market Outlook by Country
11.5 Brazil Biopharmaceutical CMO And CRO Market Outlook
11.6 Argentina Biopharmaceutical CMO And CRO Market Outlook
11.7 Other Latin America Biopharmaceutical CMO And CRO Market Outlook
12. Middle East and Africa Biopharmaceutical CMO And CRO Market Outlook and Opportunities to 2030
12.1 Market Snapshot, 2023
12.2 Middle East and AfricaBiopharmaceutical CMO And CRO Market Outlook by Application
12.3 Middle East and AfricaBiopharmaceutical CMO And CRO Market Outlook by Type
12.4 Middle East and AfricaBiopharmaceutical CMO And CRO Market Outlook by Country
12.5 Saudi Arabia Biopharmaceutical CMO And CRO Market Outlook
12.6 UAE Biopharmaceutical CMO And CRO Market Outlook
12.7 South Africa Biopharmaceutical CMO And CRO Market Outlook
12.8 Other Middle East and Africa Biopharmaceutical CMO And CRO Market Outlook
13 Profiles of major Biopharmaceutical CMO And CRO Companies
Boehringer Ingelheim GmbH
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Lonza Group
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Inno Biologics Sdn Bhd
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Rentschler Biopharma SE
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
JRS Pharma
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Biomeva GmbH
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
ProBioGen AG
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Fujifilm Holdings Corporation
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
Toyobo Co. Ltd.
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Analysis
14. Appendix
14.1 Publisher’s Expertise
14.2 List of Tables and Charts
14.3 List of Exhibits
14.4 Legal Disclaimer
• Mammalian
• Non-mammalian
By Service
• Contract Manufacturing
• Contract Research
• Monoclonal antibodies (MAbs)
• Recombinant Proteins
• Vaccines
• Antisense, RNAi, & Molecular Therapy
• Biosimilars
• Others